Authors Posts by Jay W. Belle Isle

Jay W. Belle Isle

Jay W. Belle Isle
Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.
Despite Bayer’s strident claims to the contrary, regulators in Ireland aren’t exactly certain the German company’s Essure “permanent” birth control device is a safe option. That uncertainty prompted the National Standards Authority of Ireland (NSAI) to decline renewal of Essure’s CE marking - the commercial license that allows the device to be sold in the EU.
There are two things you don't want to see being made - sausage and legislation. ~ Otto von Bismarck. This axiomatic quote says it all: you don’t want to see these things being made because the process will likely turn your stomach. The latest effort by Washington’s true masters is no less disgusting. Lobbyists for the insurance and medical industries are proudly - and loudly - claiming responsibility for a recent medical malpractice reform bill.
This week’s Feel Good Friday hits close to home for this writer. It takes a look at a serious issue and one man’s efforts to help. I’m speaking specifically about the high rate of suicide among the nation’s LGBTQ youth, the Trevor Project, an organization dedicated to helping these young people, and Jonathan Foulk, one of the workers at the Project.
As reported Monday, a $300M settlement agreement was reached between Daiichi Sankyo and users of the popular high blood pressure drug, Benicar. The settlement agreement may be read on a website, Olmesartan Products Litigation Settlement, established to facilitate payment of claims. Plaintiffs opting to enroll in the Olmesartan Products Resolution Program (at the website) must comply with enrollment requirements as spelled out on the site.
Almost two and a half years after the Judicial Panel on Multidistrict Litigation (JPML) created the Benicar MDL, the parties reached a $300M settlement. At issue was whether the manufacturers, Daiichi Sankyo and Forest Laboratories, knew or should have...
As the old saying goes, “An army marches on its stomach.” This refers to the importance of making sure one’s people are properly fed and supplied. What about lawyers, that civilian group of warriors busy fighting for justice? The same is true, though in this case, we’re talking about data, not MREs. Enter Litimetrics, “a legal technology engine for attorneys and their clients.”
Takata, the beleaguered airbag company, got hit with a trifecta of bad news this month: the 12th U.S. airbag-related fatality was announced, the reorganization bankruptcy continues with a Special Master managing restitution payments, and yet another 2.7 million airbags were recalled. The problems keep piling up faster than the Japanese auto supplier can deal with them.
Last month, I had the pleasure of reporting Lex Machina’s expansion into commercial law with their award-winning Legal Analytics® platform. Our friends haven’t been resting on their laurels after a successful launch, though. This month, the LexisNexis company launched...
The U.S. Supreme Court handed down a decision on June 19 that may change the landscape for mass tort/class action lawsuits and not in a way favorable to injured plaintiffs.
There’s potential good news for those with serious allergies: Adamis Pharmaceutical’s Symjepi, an EpiPen alternative, has been granted FDA approval. Pricing information has yet to be released to the public, but the company anticipates Symjepi will be priced well...